Doxorubicin nanoparticles - Onxeo

Drug Profile

Doxorubicin nanoparticles - Onxeo

Alternative Names: BA-003; Doxorubicin Transdrug; Doxorubicin-Transdrug; Livatag

Latest Information Update: 02 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAlliance Pharma
  • Developer CNRS; Onxeo SA
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Liver cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 26 Oct 2017 Discontinued - Clinical-Phase-Unknown for liver cancer (Combination therapy, First-line therapy) (IV)
  • 26 Oct 2017 Discontinued - Phase-II/III for liver cancer in European Union (Intra-arterial)
  • 26 Oct 2017 Discontinued - Phase-III for liver cancer (Late-stage disease, Second-line therapy or greater) in Saudi Arabia, Turkey, Spain, Lebanon, Italy, Hungary, Germany, France, Egypt, Belgium, Austria, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top